LATS1 antibody-多抗-深圳欣博盛生物科技有限公司

首页产品中心多抗

LATS1 antibody

品牌：GeneTex

官网链接

说明书

折扣/货期

货号：GTX131532	规格：100μl	目录价：￥4000
货号：GTX131532-S	规格：25μl	目录价：￥1700

产品详情

* 以下信息仅供参考，详情请以原厂网站为准

产品名称:

LATS1 antibody

别名:

large tumor suppressor kinase 1 , WARTS , wts

反应种属:

Human

宿主来源:

Rabbit

实验应用:

同种型:

IgG

免疫原:

Recombinant protein encompassing a sequence within the N-terminus region of human LATS1. The exact sequence is proprietary.

克隆性:

Polyclonal

克隆号:

纯化方式:

Purified by antigen-affinity chromatography.

偶联:

Unconjugated

产品浓度:

0.67 mg/ml (Please refer to the vial label for the specific concentration.)

保存温度:

Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.

运输温度:

4°C

预期分子量:

127

产品形式:

Liquid

存储溶液:

PBS, 20% Glycerol, 0.025% ProClin 300.

生产商:

GeneTex

功能与背景:

The protein encoded by this gene is a putative serine/threonine kinase that localizes to the mitotic apparatus and complexes with cell cycle controller CDC2 kinase in early mitosis. The protein is phosphorylated in a cell-cycle dependent manner, with late prophase phosphorylation remaining through metaphase. The N-terminal region of the protein binds CDC2 to form a complex showing reduced H1 histone kinase activity, indicating a role as a negative regulator of CDC2/cyclin A. In addition, the C-terminal kinase domain binds to its own N-terminal region, suggesting potential negative regulation through interference with complex formation via intramolecular binding. Biochemical and genetic data suggest a role as a tumor suppressor. This is supported by studies in knockout mice showing development of soft-tissue sarcomas, ovarian stromal cell tumors and a high sensitivity to carcinogenic treatments. [provided by RefSeq]

您可能感兴趣的产品

Biotinylated Anti-Human SCGF-beta

货号：500-P99GBT-25UG

Biotinylated Anti-Human Fractalkine (CX3CL1)

货号：500-P98BT-25UG

Biotinylated Anti-Human TARC (CCL17)